Australia's most trusted
source of pharma news
Posted 28 October 2025 PM
CSL has indefinitely delayed the spin-off of Seqirus, as its share price plummeted on Tuesday due to the local giant slashing its growth forecast.
The reason given for the delay in separating Seqirus was higher than expected declines in vaccination rates in the US, likely due to US Health Secretary Robert Kennedy Jr's attacks on the technology. While he has focused on removing thimersol from vaccines because antivax groups claim, without evidence, that it causes autism, a portion of the general public doesn't recognise that distinction and has reduced trust in all vaccines.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.